JP2011079792A - Cyanobacterium spirulina composition - Google Patents
Cyanobacterium spirulina composition Download PDFInfo
- Publication number
- JP2011079792A JP2011079792A JP2009234894A JP2009234894A JP2011079792A JP 2011079792 A JP2011079792 A JP 2011079792A JP 2009234894 A JP2009234894 A JP 2009234894A JP 2009234894 A JP2009234894 A JP 2009234894A JP 2011079792 A JP2011079792 A JP 2011079792A
- Authority
- JP
- Japan
- Prior art keywords
- spirulina
- phycocyanin
- weight
- tablets
- serum creatinine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000002900 Arthrospira platensis Species 0.000 title claims abstract description 84
- 235000016425 Arthrospira platensis Nutrition 0.000 title claims abstract description 43
- 229940082787 spirulina Drugs 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 241001464430 Cyanobacterium Species 0.000 title claims abstract description 32
- 108010053210 Phycocyanin Proteins 0.000 claims abstract description 58
- 239000000843 powder Substances 0.000 claims abstract description 22
- 239000001055 blue pigment Substances 0.000 claims description 28
- 230000003907 kidney function Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000049 pigment Substances 0.000 abstract description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 80
- 229940109239 creatinine Drugs 0.000 description 40
- 210000002966 serum Anatomy 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NNMALANKTSRILL-LXENMSTPSA-N 3-[(2z,5e)-2-[[3-(2-carboxyethyl)-5-[(z)-[(3e,4r)-3-ethylidene-4-methyl-5-oxopyrrolidin-2-ylidene]methyl]-4-methyl-1h-pyrrol-2-yl]methylidene]-5-[(4-ethyl-3-methyl-5-oxopyrrol-2-yl)methylidene]-4-methylpyrrol-3-yl]propanoic acid Chemical compound O=C1C(CC)=C(C)C(\C=C\2C(=C(CCC(O)=O)C(=C/C3=C(C(C)=C(\C=C/4\C(\[C@@H](C)C(=O)N\4)=C\C)N3)CCC(O)=O)/N/2)C)=N1 NNMALANKTSRILL-LXENMSTPSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- INPDFIMLLXXDOQ-UHFFFAOYSA-N Phycocyanobilin Natural products CCC1=C(C)C(=CC2=NC(=C/c3[nH]c(C=C/4C(C(C(N4)=O)C)=CC)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O INPDFIMLLXXDOQ-UHFFFAOYSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- -1 aced Chemical compound 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011475 lollipops Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 108010072011 phycocyanobilin Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004032 porphyrins Chemical group 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明は、腎臓機能を改善させる効果のある藍藻類スピルリナ組成物に関するものである。 The present invention relates to a cyanobacterium Spirulina composition having an effect of improving kidney function.
フィコシアニンは、藍藻類スピルリナに多く含まれている光合成色素の一つであるが、水溶性の蛋白質であるので、水溶液とすることができる。フィコシアニンの水溶液は、明るい青色を呈する。この水溶液とすると明るい青色を呈するフィコシアニンは、従来からチューインガムやアイスキャンディー等の食品を着色する為の天然色素の主成分として知られている。また、フィコシアニンは、人や動物の胆汁色素と同じ構造を有しているので、生体に関わりが深い物質であることもわかっている。 Phycocyanin is one of the photosynthetic pigments abundantly contained in the cyanobacterium Spirulina, but since it is a water-soluble protein, it can be made into an aqueous solution. An aqueous solution of phycocyanin exhibits a bright blue color. Phycocyanin, which exhibits a bright blue color when used as an aqueous solution, has been conventionally known as a main component of natural pigments for coloring foods such as chewing gum and ice lolly. It is also known that phycocyanin is a substance closely related to living organisms because it has the same structure as human and animal bile pigments.
従来、フィコシアニンが、生理活性作用、特に、腎臓機能改善作用を有していることが報告されているが、フィコシアニンを含有する薬剤としては、フィコシアニンを含有している藍藻類スピルリナ、又は、藍藻類スピルリナの水溶性画分、を有効成分とする腎臓疾患予防用薬剤（特許文献１を参照。）が提案されている。 Conventionally, it has been reported that phycocyanin has a physiologically active action, in particular, a kidney function improving action. A drug for preventing kidney disease containing a water-soluble fraction of spirulina as an active ingredient (see Patent Document 1) has been proposed.
前記藍藻類スピルリナ、又は、藍藻類スピルリナの水溶性画分に含有されているフィコシアニンは、通常、２〜４％程度のフィコシアニンを含有しているが、これらの藍藻類スピルリナ、又は、藍藻類スピルリナの水溶性画分、を有効成分として含有する腎臓疾患予防用薬剤は、前述のとおり、フィコシアニンの含有量が２〜４％程度と少ないので、血清クレアチニンを十分に低下させることができず、そのために、腎臓機能を十分に改善させることができない、という問題があった。 The phycocyanin contained in the cyanobacteria spirulina or the water-soluble fraction of the cyanobacterium Spirulina usually contains about 2 to 4% of phycocyanin, but these cyanobacteria spirulina or cyanobacteria spirulina As described above, since the phycocyanin content is as low as 2 to 4%, the drug for preventing kidney disease containing the water-soluble fraction of the above as an active ingredient cannot sufficiently reduce serum creatinine. In addition, there was a problem that kidney function could not be improved sufficiently.
本発明は、かかる問題を解決することを目的としている。 The present invention aims to solve this problem.
即ち、本発明は、腎臓機能を回復させる効果をいっそう向上させた藍藻類スピルリナ組成物を提供することを目的としている。 That is, an object of the present invention is to provide a cyanobacterium Spirulina composition that further improves the effect of restoring kidney function.
請求項１に記載された発明は、上記目的を達成するために、藍藻類スピルリナ粉末１００重量部と前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素６〜２０重量部とを含有していることを特徴とする藍藻類スピルリナ組成物である。
In order to achieve the above object, the invention described in
請求項１に記載された発明によれば、藍藻類スピルリナ粉末１００重量部と前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素６〜２０重量部とを含有している藍藻類スピルリナ組成物とするので、腎臓機能を回復させる効果をいっそう向上させた藍藻類スピルリナ組成物を提供することができる。
According to the invention described in
フィコシアニンは、ポルフィリン環が開環したテトラピロール構造を有するフィコシアノビリンと呼ばれる色素部分と蛋白質とがペプチド結合した水溶性の色素蛋白質の構造をもっている。 Phycocyanin has a structure of a water-soluble chromoprotein in which a pigment part called phycocyanobilin having a tetrapyrrole structure in which a porphyrin ring is opened and a protein are peptide-bonded.
フィコシアニンの性質に最も大きな影響を及ぼしているのは、分子の大部分を占めている蛋白質部分であるので、フィコシアニンは、蛋白質としての性質を持っており、そのために、フィコシアニンは、蛋白質としての強さ、弱さを持っている。 The most significant influence on the properties of phycocyanin is the protein portion that occupies the majority of the molecule, so phycocyanin has the properties of a protein, and therefore phycocyanin is a strong protein as a protein. I have weakness.
フィコシアニンは、赤色光を吸収するので、その水溶液は青色を呈する。また、フィコシアニンは、極大吸収波長を６１８ｎｍとする赤色の蛍光を発する蛍光物質である。 Because phycocyanin absorbs red light, its aqueous solution exhibits a blue color. Phycocyanin is a fluorescent substance that emits red fluorescence with a maximum absorption wavelength of 618 nm.
フィコシアニンは、通常、３量体又は６量体を形成している。単量体は、α、βのポリペプチドで構成されているが、フィコシアニンの場合、α＝１６，０００、β＝２０，０００であるので、その分子量は、約１１万又は２２万であると推定される。また、フィコシアニンは、等電点を４．３とする酸性蛋白質であるので、その水溶液は、アルカリ性では不安定となるが、ｐＨ５〜７では安定となる。 Phycocyanin usually forms a trimer or a hexamer. The monomer is composed of α and β polypeptides, but in the case of phycocyanin, α = 16,000 and β = 20,000, so that the molecular weight is about 110,000 or 220,000. Presumed. Further, since phycocyanin is an acidic protein having an isoelectric point of 4.3, its aqueous solution is unstable when alkaline but is stable at pH 5-7.
スピルリナには、フィコシアニンの他に、フィコビリン蛋白質として、フィコエリトリン及びアロフィコシアニンが含まれており、その吸収曲線は、実際にはこの３本のピークが重なっている。 In addition to phycocyanin, spirulina contains phycoerythrin and allophycocyanin as phycobilin proteins, and the absorption curves actually overlap these three peaks.
フィコシアニンは、冷水又は４０℃以下の温水に速やかに溶解し、明るい青色の水溶液となる。水１００ｇ当たりの溶解度は約１０ｇである。フィコシアニンは、エタノール、アセド、エーテル等の有機溶媒には不溶である。その理由は、蛋白質がエタノール、アセド、エーテル等の有機溶媒で変性されて、沈殿を生成するためである。しかしながら、フィコシアニンは、２０％以下のエタノール水溶液には溶解するが、不安定で徐々に沈殿を生ずる。 Phycocyanin quickly dissolves in cold water or warm water of 40 ° C. or lower, and becomes a bright blue aqueous solution. The solubility per 100 g of water is about 10 g. Phycocyanin is insoluble in organic solvents such as ethanol, acetate, and ether. The reason is that the protein is denatured with an organic solvent such as ethanol, aced, ether, and the like to form a precipitate. However, phycocyanin dissolves in an aqueous ethanol solution of 20% or less, but is unstable and gradually precipitates.
フィコシアニンは、水溶液の場合は、４０℃以上で急速に暗色化するが、粉末（水分量８％以下）の場合は、１１０℃で２時間加熱を行っても変化しない。また、フィコシアニンは、水溶液の場合、アルカリ側より酸性側が安定であるが、一般的に、光に対しては退色率が大きい。 In the case of an aqueous solution, phycocyanin darkens rapidly at 40 ° C. or more, but in the case of powder (moisture content of 8% or less), phycocyanin does not change even when heated at 110 ° C. for 2 hours. In the case of an aqueous solution, phycocyanin is more stable on the acidic side than on the alkali side, but generally has a large fading rate for light.
フィコシアニンを主成分とする青色色素は、
（１）噴霧乾燥したスピルリナを水に浸漬してフィコシアニンを抽出することによりフィコシアニン抽出液を得る工程、
（２）前記フィコシアニン抽出液からスピルリナの水不溶部分を遠心分離機を用いて分離除去する工程、
（３）前記スピルリナの水不溶部分を分離除去したフィコシアニン抽出液を限外濾過膜を用いて、分子量分画を行い、分子量１５，０００以下の水溶性部分を分離除去する工程、
（４）前記分子量１５，０００以下の水溶性部分を分離除去したフィコシアニン抽出液からフィコシアニンを分離する工程、
（５）前記分離されたフィコシアニンを限外濾過膜で濃縮する工程、
（６）前記濃縮したフィコシアニンに副原料を加えて、これらを噴霧乾燥することにより、フィコシアニンを主成分とする粉末状の青色色素を得る工程、及び、
（７）前記粉末状の青色色素を熱風乾燥機を用いて殺菌する工程
を順次経て製造される。
Blue pigments based on phycocyanin are
(1) A step of obtaining a phycocyanin extract by immersing spray-dried spirulina in water and extracting phycocyanin;
(2) A step of separating and removing a water-insoluble portion of Spirulina from the phycocyanin extract using a centrifuge,
(3) A step of performing molecular weight fractionation of the phycocyanin extract obtained by separating and removing the water-insoluble part of Spirulina using an ultrafiltration membrane, and separating and removing a water-soluble part having a molecular weight of 15,000 or less,
(4) A step of separating phycocyanin from the phycocyanin extract obtained by separating and removing the water-soluble part having a molecular weight of 15,000 or less,
(5) a step of concentrating the separated phycocyanin with an ultrafiltration membrane,
(6) adding a secondary material to the concentrated phycocyanin and spray-drying them to obtain a powdery blue pigment mainly composed of phycocyanin; and
(7) Manufactured sequentially through the step of sterilizing the powdery blue pigment using a hot air dryer.
本発明の藍藻類スピルリナ組成物は、藍藻類スピルリナ粉末１００重量部と前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素６〜２０重量部とを含有している。 The cyanobacteria spirulina composition of the present invention contains 100 parts by weight of cyanobacteria spirulina powder and 6 to 20 parts by weight of a blue pigment mainly composed of phycocyanin extracted from the cyanobacterium Spirulina.
藍藻類スピルリナの粉末１００重量部に対する前記スピルリナより抽出したフィコシアニンを主成分とする青色色素の添加量が６重量部未満であると、後述する比較例１〜３に示されているように、健康な男性における血清クレアチニン濃度の正常値：０．６０〜１．２０ｍｇ／ｄｌの範囲に低下させることができないが、藍藻類スピルリナの粉末１００重量部に対する前記スピルリナより抽出したフィコシアニンを主成分とする青色色素の添加量が６〜２０重量部であると、後述する実施例１〜８に示されているように、錠剤投与７日後の血清クレアチニン濃度（ｍｇ／ｄｌ）が、健康な男性における血清クレアチニン濃度の正常値：０．６０〜１．２０ｍｇ／ｄｌの範囲に低下させることができる。また、前記藍藻類スピルリナの粉末１００重量部に対する前記スピルリナより抽出したフィコシアニンを主成分とする青色色素の添加量が２０重量部を超えても、健康な男性における血清クレアチニン濃度の正常値：０．６０〜１．２０ｍｇ／ｄｌの範囲に低下させることができるが、前記フィコシアニンを主成分とする青色色素は高価であるので、前記藍藻類スピルリナ組成物の製造コストを上げるこことなり好ましくない。したがって、前記藍藻類スピルリナ粉末１００重量部に対する前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素の含有量は、６〜２０重量部である。 As shown in Comparative Examples 1 to 3 to be described later, when the amount of the blue pigment mainly composed of phycocyanin extracted from the spirulina is less than 6 parts by weight with respect to 100 parts by weight of the cyanobacterium Spirulina powder, Normal value of serum creatinine concentration in healthy men: blue that contains phycocyanin extracted from spirulina as a main component but cannot be reduced to a range of 0.60 to 1.20 mg / dl, but to 100 parts by weight of the cyanobacterium spirulina powder When the added amount of the dye is 6 to 20 parts by weight, the serum creatinine concentration (mg / dl) 7 days after tablet administration is shown in Examples 1 to 8 to be described later, the serum creatinine in healthy men Normal value of concentration: can be lowered to a range of 0.60 to 1.20 mg / dl. In addition, even when the amount of blue pigment containing phycocyanin extracted from spirulina as a main component exceeds 100 parts by weight with respect to 100 parts by weight of the cyanobacterium Spirulina powder, the normal value of serum creatinine concentration in healthy men: 0. Although it can be reduced to a range of 60 to 1.20 mg / dl, the blue pigment containing phycocyanin as a main component is expensive, which is not preferable because it increases the production cost of the cyanobacterium Spirulina composition. Therefore, the content of the blue pigment mainly composed of phycocyanin extracted from the cyanobacteria spirulina with respect to 100 parts by weight of the cyanobacteria spirulina powder is 6 to 20 parts by weight.
このように、藍藻類スピルリナ粉末１００と前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素６〜２０重量部とを含有していると、腎臓機能を回復させる効果をいっそう向上させた藍藻類スピルリナ組成物を提供することができる。
Thus, when the
本発明の藍藻類スピルリナ組成物は、粉末状、粒状、又は、カプセルとされて、薬剤製品とされるが、本発明の藍藻類スピルリナ組成物は、好ましくは、打錠機で打錠されて錠剤とされる。 The cyanobacteria spirulina composition of the present invention is powdered, granular, or capsuled to form a pharmaceutical product, but the cyanobacterium spirulina composition of the present invention is preferably compressed by a tableting machine. It is considered as a tablet.
以下に、本発明の実施例を説明するが、本発明はこれらの実施例に限定されるものではない。 Examples of the present invention will be described below, but the present invention is not limited to these examples.
（実施例１）
藍藻類スピルリナ粉末１００重量に前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素６重量部を添加して藍藻類スピルリナ組成物とし、この藍藻類スピルリナ組成物を打錠機で打錠して錠剤とした。そして、このようにして得た錠剤を血清クレアチニン濃度２．５０ｍｇ／ｄｌの男性患者１０名に毎日２０錠（０．２ｇ／錠×２０錠）７日間投与して、毎日、血清クレアチニン濃度の測定を行った。測定結果は、次の表１
A blue-green algae spirulina composition is prepared by adding 6 parts by weight of a blue pigment mainly composed of phycocyanin extracted from the cyanobacteria spirulina to 100 weight of the cyanobacterium spirulina powder, and the cyanobacteria spirulina composition is compressed by a tableting machine. Into tablets. The tablets thus obtained were administered to 10 male patients with a serum creatinine concentration of 2.50 mg / dl for 20 days daily (0.2 g / tablet × 20 tablets) for 7 days, and the serum creatinine concentration was measured daily. Went. The measurement results are shown in Table 1 below.
（実施例２）
藍藻類スピルリナ粉末１００重量に前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素８重量部を添加して藍藻類スピルリナ組成物とし、この藍藻類スピルリナ組成物を打錠機で打錠して錠剤とした。そして、このようにして得た錠剤を血清クレアチニン濃度２．５０ｍｇ／ｄｌの男性患者１０名に毎日２０錠（０．２ｇ／錠×２０錠）７日間投与して、毎日、血清クレアチニン濃度の測定を行った。測定結果は、次の表２
A blue-green algae spirulina composition is prepared by adding 8 parts by weight of a blue pigment mainly composed of phycocyanin extracted from the cyanobacteria spirulina to 100 weight of the cyanobacterium spirulina powder, and the cyanobacteria spirulina composition is compressed by a tableting machine. Into tablets. The tablets thus obtained were administered to 10 male patients with a serum creatinine concentration of 2.50 mg / dl for 20 days daily (0.2 g / tablet × 20 tablets) for 7 days, and the serum creatinine concentration was measured daily. Went. The measurement results are shown in Table 2 below.
（実施例３）
藍藻類スピルリナ粉末１００重量に前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素１０重量部を添加して藍藻類スピルリナ組成物とし、この藍藻類スピルリナ組成物を打錠機で打錠して錠剤とした。そして、このようにして得た錠剤を血清クレアチニン濃度２．５０ｍｇ／ｄｌの男性患者１０名に毎日２０錠（０．２ｇ／錠×２０錠）７日間投与して、毎日、血清クレアチニン濃度の測定を行った。測定結果は、次の表３
10 parts by weight of a blue pigment mainly composed of phycocyanin extracted from the cyanobacteria spirulina is added to 100 weight of the cyanobacterium spirulina powder to form a cyanobacteria spirulina composition, and the cyanobacteria spirulina composition is compressed by a tableting machine. Into tablets. The tablets thus obtained were administered to 10 male patients with a serum creatinine concentration of 2.50 mg / dl for 20 days (0.2 g / tablet × 20 tablets) daily for 7 days, and the serum creatinine concentration was measured daily. Went. The measurement results are shown in Table 3 below.
（実施例４）
藍藻類スピルリナ粉末１００重量に前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素１２重量部を添加して藍藻類スピルリナ組成物とし、この藍藻類スピルリナ組成物を打錠機で打錠して錠剤とした。そして、このようにして得た錠剤を血清クレアチニン濃度２．５０ｍｇ／ｄｌの男性患者１０名に毎日２０錠（０．２ｇ／錠×２０錠）７日間投与して、毎日、血清クレアチニン濃度の測定を行った。測定結果は、次の表４
The blue-green algae spirulina composition is prepared by adding 12 parts by weight of a blue pigment mainly composed of phycocyanin extracted from the cyanobacteria spirulina to 100 weight of the cyanobacteria spirulina powder. Into tablets. The tablets thus obtained were administered to 10 male patients with a serum creatinine concentration of 2.50 mg / dl for 20 days daily (0.2 g / tablet × 20 tablets) for 7 days, and the serum creatinine concentration was measured daily. Went. The measurement results are shown in Table 4 below.
（実施例５）
藍藻類スピルリナ粉末１００重量に前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素１４重量部を添加して藍藻類スピルリナ組成物とし、この藍藻類スピルリナ組成物を打錠機で打錠して錠剤とした。そして、このようにして得た錠剤を血清クレアチニン濃度２．５０ｍｇ／ｄｌの男性患者１０名に毎日２０錠（０．２ｇ／錠×２０錠）７日間投与して、毎日、血清クレアチニン濃度の測定を行った。測定結果は、次の表５
The blue-green algae spirulina composition is prepared by adding 14 parts by weight of a blue pigment mainly composed of phycocyanin extracted from the cyanobacteria spirulina to 100 weight of the cyanobacteria spirulina powder, and the cyanobacteria spirulina composition is compressed by a tableting machine. Into tablets. The tablets thus obtained were administered to 10 male patients with a serum creatinine concentration of 2.50 mg / dl for 20 days daily (0.2 g / tablet × 20 tablets) for 7 days, and the serum creatinine concentration was measured daily. Went. The measurement results are shown in Table 5 below.
（実施例６）
藍藻類スピルリナ粉末１００重量に前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素１６重量部を添加して藍藻類スピルリナ組成物とし、この藍藻類スピルリナ組成物を打錠機で打錠して錠剤とした。そして、このようにして得た錠剤を血清クレアチニン濃度２．５０ｍｇ／ｄｌの男性患者１０名に毎日２０錠（０．２ｇ／錠×２０錠）７日間投与して、毎日、血清クレアチニン濃度の測定を行った。測定結果は、次の表６
16 parts by weight of a blue pigment mainly composed of phycocyanin extracted from the cyanobacteria spirulina is added to 100 weight of the cyanobacterium spirulina powder to obtain a cyanobacteria spirulina composition, and the cyanobacteria spirulina composition is compressed by a tableting machine. Into tablets. The tablets thus obtained were administered to 10 male patients with a serum creatinine concentration of 2.50 mg / dl for 20 days daily (0.2 g / tablet × 20 tablets) for 7 days, and the serum creatinine concentration was measured daily. Went. The measurement results are shown in Table 6 below.
（実施例７）
藍藻類スピルリナ粉末１００重量に前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素１８重量部を添加して藍藻類スピルリナ組成物とし、この藍藻類スピルリナ組成物を打錠機で打錠して錠剤とした。そして、このようにして得た錠剤を血清クレアチニン濃度２．５０ｍｇ／ｄｌの男性患者１０名に毎日２０錠（０．２ｇ／錠×２０錠）７日間投与して、毎日、血清クレアチニン濃度の測定を行った。測定結果は、次の表７
A blue-green algae spirulina composition is prepared by adding 18 parts by weight of a blue pigment mainly composed of phycocyanin extracted from the cyanobacterium spirulina to 100 weight of the cyanobacteria spirulina powder, and the cyanobacteria spirulina composition is compressed by a tableting machine. Into tablets. The tablets thus obtained were administered to 10 male patients with a serum creatinine concentration of 2.50 mg / dl for 20 days daily (0.2 g / tablet × 20 tablets) for 7 days, and the serum creatinine concentration was measured daily. Went. The measurement results are shown in Table 7 below.
（実施例８）
藍藻類スピルリナ粉末１００重量に前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素２０重量部を添加して藍藻類スピルリナ組成物とし、この藍藻類スピルリナ組成物を打錠機で打錠して錠剤とした。そして、このようにして得た錠剤を血清クレアチニン濃度２．５０ｍｇ／ｄｌの男性患者１０名に毎日２０錠（０．２ｇ／錠×２０錠）７日間投与して、毎日、血清クレアチニン濃度の測定を行った。測定結果は、次の表８
20 parts by weight of a blue pigment mainly composed of phycocyanin extracted from the cyanobacteria spirulina is added to 100 weight of the cyanobacterium spirulina powder to obtain a cyanobacteria spirulina composition, and the cyanobacteria spirulina composition is compressed by a tableting machine. Into tablets. The tablets thus obtained were administered to 10 male patients with a serum creatinine concentration of 2.50 mg / dl for 20 days daily (0.2 g / tablet × 20 tablets) for 7 days, and the serum creatinine concentration was measured daily. Went. The measurement results are shown in Table 8 below.
（比較例１）
藍藻類スピルリナ粉末１００重量に前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素０．１重量部を添加して藍藻類スピルリナ組成物とし、この藍藻類スピルリナ組成物を打錠機で打錠して錠剤とした。そして、このようにして得た錠剤を血清クレアチニン濃度２．５０ｍｇ／ｄｌの男性患者１０名に毎日２０錠（０．２ｇ／錠×２０錠）７日間投与して、毎日、血清クレアチニン濃度の測定を行った。測定結果は、次の表９
The blue-green algae spirulina composition was prepared by adding 0.1 part by weight of a blue pigment mainly composed of phycocyanin extracted from the cyanobacteria spirulina to 100 weight of the cyanobacterium spirulina powder. Tablets were made into tablets. The tablets thus obtained were administered to 10 male patients with a serum creatinine concentration of 2.50 mg / dl for 20 days daily (0.2 g / tablet × 20 tablets) for 7 days, and the serum creatinine concentration was measured daily. Went. The measurement results are shown in Table 9 below.
（比較例２）
藍藻類スピルリナ粉末１００重量に前記藍藻類スピルリナより抽出したフィコシアニンを主成分とする青色色素５．０重量部を添加して藍藻類スピルリナ組成物とし、この藍藻類スピルリナ組成物を打錠機で打錠して錠剤とした。そして、このようにして得た錠剤を血清クレアチニン濃度２．５０ｍｇ／ｄｌの男性患者１０名に毎日２０錠（０．２ｇ／錠×２０錠）７日間投与して、毎日、血清クレアチニン濃度の測定を行った。測定結果は、次の表１０
A blue pigment mainly composed of phycocyanin extracted from the cyanobacteria spirulina is added to 100 weight of the cyanobacterium spirulina powder to obtain a cyanobacteria spirulina composition, and the cyanobacteria spirulina composition is punched with a tableting machine. Tablets were made into tablets. The tablets thus obtained were administered to 10 male patients with a serum creatinine concentration of 2.50 mg / dl for 20 days daily (0.2 g / tablet × 20 tablets) for 7 days, and the serum creatinine concentration was measured daily. Went. The measurement results are shown in Table 10 below.
（比較例３）
藍藻類スピルリナ粉末のみよりなる藍藻類スピルリナ組成物を打錠機で打錠して錠剤とした。そして、このようにして得た錠剤を血清クレアチニン濃度２．５０ｍｇ／ｄｌの男性患者１０名に毎日２０錠（０．２ｇ／錠×２０錠）７日間投与して、毎日、血清クレアチニン濃度の測定を行った。測定結果は、次の表１１
A cyanobacterial spirulina composition consisting only of cyanobacteria spirulina powder was compressed into tablets using a tableting machine. The tablets thus obtained were administered to 10 male patients with a serum creatinine concentration of 2.50 mg / dl for 20 days daily (0.2 g / tablet × 20 tablets) for 7 days, and the serum creatinine concentration was measured daily. Went. The measurement results are shown in Table 11 below.
以上、実施例１〜８及び比較例１〜３に記載された「錠剤の錠剤投与後の日数」と「血清クレアチニン濃度（ｍｇ／ｄｌ）」との関係は、図１に示される。図１において、横軸は、錠剤投与後の日数（日）であり、そして、縦軸は、血清クレアチニン濃度（ｍｇ／ｄｌ）である。また、実施例１〜８及び比較例１〜３に記載された「錠剤における青色色素添加量（重量部）」と「７日後の血清クレアチニン濃度（ｍｇ／ｄｌ）」との関係は、図２に示される。図２において、横軸は、青色色素添加量（重量部）であり、そして、縦軸は、７日後の血清クレアチニン濃度（ｍｇ／ｄｌ）である。 The relationship between “the number of days after tablet administration” and “serum creatinine concentration (mg / dl)” described in Examples 1 to 8 and Comparative Examples 1 to 3 is shown in FIG. In FIG. 1, the horizontal axis represents the number of days (day) after tablet administration, and the vertical axis represents the serum creatinine concentration (mg / dl). In addition, the relationship between “blue pigment addition amount (parts by weight)” in tablets and “serum creatinine concentration after 7 days (mg / dl)” described in Examples 1 to 8 and Comparative Examples 1 to 3 is shown in FIG. Shown in In FIG. 2, the horizontal axis represents the amount of blue pigment added (parts by weight), and the vertical axis represents the serum creatinine concentration (mg / dl) after 7 days.
図１から次のことがわかる。即ち、実施例１〜８は、藍藻類スピルリナ粉末１００重量部に、フィコシアニンを主成分とする青色色素６重量部、８重量部、１０重量部、１２重量部、１４重量部、１６重量部、１８重量部及び２０重量部を、それぞれ、添加した錠剤を投与したものであり、比較例１，２は、フィコシアニンを主成分とする青色色素０．１重量部及び５．０重量部を、それぞれ、添加した錠剤を投与したものであり、そして、比較例３は、フィコシアニンを主成分とする青色色素を添加しない錠剤を投与したものであるが、図１からは、次のことがわかる。即ち、実施例１〜８では、血清クレアチニン濃度（ｍｇ／ｄｌ）が錠剤投与７日後まで急激に低下するのに対して、比較例１〜３では、血清クレアチニン濃度（ｍｇ／ｄｌ）が錠剤投与７日後まで緩やかに低下するに過ぎない。また、図２からは、実施例１〜８では、錠剤投与７日後の血清クレアチニン濃度（ｍｇ／ｄｌ）が、健康な男性における血清クレアチニン濃度の正常値：０．６０〜１．２０ｍｇ／ｄｌの範囲に低下するのに対して、比較例１〜３では、健康な男性における血清クレアチニン濃度の正常値：０．６０〜１．２０ｍｇ／ｄｌの範囲に低下しない。 The following can be seen from FIG. That is, in Examples 1 to 8, 6 parts by weight, 8 parts by weight, 10 parts by weight, 12 parts by weight, 14 parts by weight, 16 parts by weight of blue pigment mainly containing phycocyanin, 18 parts by weight and 20 parts by weight were respectively administered with added tablets, and Comparative Examples 1 and 2 were respectively 0.1 parts by weight and 5.0 parts by weight of a blue pigment mainly composed of phycocyanin. In the comparative example 3, the tablet to which the blue pigment mainly composed of phycocyanin was not added was administered, and FIG. 1 shows the following. That is, in Examples 1 to 8, the serum creatinine concentration (mg / dl) decreases sharply until 7 days after tablet administration, whereas in Comparative Examples 1 to 3, the serum creatinine concentration (mg / dl) is administered to the tablet. It declines only slowly until 7 days later. 2, in Examples 1 to 8, the serum creatinine concentration (mg / dl) 7 days after tablet administration was a normal value of the serum creatinine concentration in healthy men: 0.60 to 1.20 mg / dl. On the other hand, in Comparative Examples 1 to 3, the serum creatinine concentration in healthy men is not lowered to a range of 0.60 to 1.20 mg / dl.
Claims (1)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009234894A JP2011079792A (en) | 2009-10-09 | 2009-10-09 | Cyanobacterium spirulina composition |
| TW099101179A TWI386216B (en) | 2009-10-09 | 2010-01-18 | Cyanophyceae spirulina composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009234894A JP2011079792A (en) | 2009-10-09 | 2009-10-09 | Cyanobacterium spirulina composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011079792A true JP2011079792A (en) | 2011-04-21 |
| JP2011079792A5 JP2011079792A5 (en) | 2012-10-25 |
Family
ID=44074239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009234894A Pending JP2011079792A (en) | 2009-10-09 | 2009-10-09 | Cyanobacterium spirulina composition |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2011079792A (en) |
| TW (1) | TWI386216B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019054472A1 (en) * | 2017-09-14 | 2019-03-21 | 三栄源エフ・エフ・アイ株式会社 | Method for suppressing bubbling in naturally derived water-soluble pigment |
| KR102101988B1 (en) * | 2019-07-25 | 2020-05-12 | 주식회사 네이처코아젠팜스 | A preparation method for for enzyme treated-spirulina hydrolysate with improved heat stability and increased phycocyanin |
| CN117837769A (en) * | 2024-01-24 | 2024-04-09 | 河海大学 | Phycocyanin effervescent tablet and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01316326A (en) * | 1988-03-11 | 1989-12-21 | Dainippon Ink & Chem Inc | Drug for preventing renal disease |
| JP2001008665A (en) * | 1999-06-25 | 2001-01-16 | Minoru Yoneda | Food dealing with endocrine disruptor |
| JP2001037454A (en) * | 1999-07-30 | 2001-02-13 | Dainippon Ink & Chem Inc | Method for producing deodorant algae |
| JP2001157559A (en) * | 1999-11-30 | 2001-06-12 | Minoru Yoneda | New food composition |
| JP2001204426A (en) * | 2000-01-21 | 2001-07-31 | Minoru Yoneda | Food for preventing disease of lifestyle habit |
| JP2003313452A (en) * | 2002-04-19 | 2003-11-06 | Dainippon Ink & Chem Inc | Spirulina granules and method for producing the same |
-
2009
- 2009-10-09 JP JP2009234894A patent/JP2011079792A/en active Pending
-
2010
- 2010-01-18 TW TW099101179A patent/TWI386216B/en active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01316326A (en) * | 1988-03-11 | 1989-12-21 | Dainippon Ink & Chem Inc | Drug for preventing renal disease |
| JP2001008665A (en) * | 1999-06-25 | 2001-01-16 | Minoru Yoneda | Food dealing with endocrine disruptor |
| JP2001037454A (en) * | 1999-07-30 | 2001-02-13 | Dainippon Ink & Chem Inc | Method for producing deodorant algae |
| JP2001157559A (en) * | 1999-11-30 | 2001-06-12 | Minoru Yoneda | New food composition |
| JP2001204426A (en) * | 2000-01-21 | 2001-07-31 | Minoru Yoneda | Food for preventing disease of lifestyle habit |
| JP2003313452A (en) * | 2002-04-19 | 2003-11-06 | Dainippon Ink & Chem Inc | Spirulina granules and method for producing the same |
Non-Patent Citations (1)
| Title |
|---|
| JPN6013053479; 衛生化学 Ｖｏｌ．３６, 1990, ｐ．５ * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019054472A1 (en) * | 2017-09-14 | 2019-03-21 | 三栄源エフ・エフ・アイ株式会社 | Method for suppressing bubbling in naturally derived water-soluble pigment |
| CN111108157A (en) * | 2017-09-14 | 2020-05-05 | 三荣源有限公司 | Method for inhibiting foaming of water-soluble pigment of natural origin |
| EP3683277A4 (en) * | 2017-09-14 | 2020-10-28 | San-Ei Gen F.F.I., INC. | Method for suppressing bubbling in naturally derived water-soluble pigment |
| KR102101988B1 (en) * | 2019-07-25 | 2020-05-12 | 주식회사 네이처코아젠팜스 | A preparation method for for enzyme treated-spirulina hydrolysate with improved heat stability and increased phycocyanin |
| WO2021015600A1 (en) * | 2019-07-25 | 2021-01-28 | 주식회사 네이처코아젠팜스 | Preparation method for spirulina hydrolysates prepared using enzyme and having improved thermostability and increased phycocyanin content |
| CN117837769A (en) * | 2024-01-24 | 2024-04-09 | 河海大学 | Phycocyanin effervescent tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201113025A (en) | 2011-04-16 |
| TWI386216B (en) | 2013-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101783469B1 (en) | Extraction method of collagens from plant | |
| JP2004250445A (en) | Glycation inhibitor and its use | |
| JP2010248212A (en) | Glycation inhibitors and uses thereof | |
| CN101353380A (en) | Collagen peptide with immune enhancing activity derived from jellyfish and its preparation and application | |
| CN116173189B (en) | Skin care composition, preparation method and application thereof | |
| JP2015042688A (en) | Vascular improver | |
| JP2011079792A (en) | Cyanobacterium spirulina composition | |
| CN105886278A (en) | Health care cocktail composition and preparation method thereof | |
| TW201427610A (en) | Skin condition amelioration agent | |
| JP4637198B2 (en) | Propolis composition and method for producing the same | |
| JP4334189B2 (en) | AGE production inhibitor | |
| CN108277251A (en) | A kind of fish skin collagen peptide and preparation method thereof | |
| KR101938348B1 (en) | Method for separating fattic acid oil and water-soluble peptide from grub | |
| KR101194947B1 (en) | Pharmaceutical composition for treating liver diseases comprising dendropanax morbifera lev | |
| JP2009137920A (en) | Glycogen phosphorylase inhibitor | |
| JP2004346132A (en) | Flavan compound-containing composition | |
| JP2010043035A (en) | Oral administration composition containing plant of genus salacia | |
| JP4610730B2 (en) | Composition for calcium supplementation | |
| CN114698845B (en) | Application of pachyman EGC composition in inhibiting formation of gastrointestinal argininyl | |
| JP2016108265A (en) | Persistent antioxidant | |
| JP7423780B2 (en) | Method for producing purified Salacia plant extract | |
| JP2010195720A (en) | Tripeptide having osteocyte proliferating action and method for producing the same | |
| KR100637018B1 (en) | Anticoronavirus composition comprising Houttuynia cordata Thunberg extract | |
| JP2011087501A (en) | Method for producing tetrapeptide having nail keratin increasing action | |
| CN106806887A (en) | A kind of composition and its application for the tender skin light color of private parts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120613 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120910 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131029 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140311 |